Clinical Pharmacokinetic Study of Lurbinectedin in Patients With Advanced Solid Tumors and Varying Degrees of Hepatic Impairment
Summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
- Rubin Lubomirov, MD, PhD
PharmaMar
Study Director - Sara Martínez González, MD
PharmaMar
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
6 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Hospital Universitario Virgen de la Victoria
Málaga, Andalusia, Spain
Recruiting - Hospital Universitari Vall D'Hebron
Barcelona, Catalonia, Spain
Recruiting - Hospital General Universitario Gregorio Marañón
Madrid, Spain
Recruiting - Hospital Universitario Fundación Jimenez Diaz
Madrid, Spain
Recruiting - Hospital Universitario Hm Sanchinarro
Madrid, Spain
Recruiting - Hospital Universitario Ramón Y Cajal
Madrid, Spain
Active, not recruiting
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 9 Mar 2021
- Primary completion
- 1 Jun 2025
- Completion
- 1 Jun 2025
- Last update posted
- 27 Nov 2023
- Registered enrollment
- 24
- Registry id
- NCT05101265
Cross-registrations
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 4 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.